The assay identifies a biologically low-risk subgroup within clinically high-risk patients, with outcomes similar to stage I disease, potentially sparing 30,000 women each year from unnecessary treatment intensification
August 25, 2025
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
The assay identifies a biologically low-risk subgroup within clinically high-risk patients, with outcomes similar to stage I disease, potentially sparing 30,000 women each year from unnecessary treatment intensification